Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VZV mRNA vaccine (RNACure Biopharma)
- Development stage
- Preclinical
- Lead developer
- RNACure Biopharma
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The VZV mRNA vaccine is an investigational prophylactic vaccine candidate being developed by RNACure Biopharma. Utilizing the company's proprietary mRNA technology platform, the vaccine is designed to prevent infections caused by the Varicella-Zoster Virus (VZV), which manifests as chickenpox (varicella) primarily in children and shingles (herpes zoster) in adults. The vaccine functions by delivering messenger RNA that encodes specific VZV antigens into the recipient's cells. These cells then translate the mRNA into viral proteins, which are presented to the immune system to elicit both neutralizing antibodies and T-cell mediated immunity. This mRNA-based approach is intended to provide a robust and potentially safer alternative to traditional live-attenuated or recombinant protein subunit vaccines.
- Other names
- Varicella-Zoster Virus mRNA vaccineShingles/chickenpox mRNA vaccineVZV mRNA Vaccine
Beyond the preview
Go deeper on VZV mRNA vaccine (RNACure Biopharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VZV mRNA vaccine (RNACure Biopharma).